SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Fermenta Biotech - Quaterly Results

14 Feb 2022 Evaluate
The revenue for the December 2021 quarter is pegged at Rs. 854.08 millions against Rs. 876.70 millions recorded during the year-ago period.A radical decline of -83.57% was reported in the net profit of the company for the quarter ended December 2021 to Rs. 18.16  millions from Rs. 110.50 millions.Operating Profit reported a sharp decline to 134.04 millions from 238.14 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 854.08 876.70 -2.58 2933.02 2819.18 4.04 3728.22 3005.07 24.06
Other Income 11.32 6.61 71.26 45.56 28.75 58.47 66.18 123.13 -46.25
PBIDT 134.04 238.14 -43.71 619.44 785.31 -21.12 1003.36 818.05 22.65
Interest 41.25 39.63 4.09 127.49 130.56 -2.35 180.75 193.20 -6.44
PBDT 92.79 198.51 -53.26 491.95 654.75 -24.86 822.61 624.85 31.65
Depreciation 62.10 46.73 32.89 176.47 130.89 34.82 190.31 149.38 27.40
PBT 30.69 151.78 -79.78 315.48 523.86 -39.78 632.30 475.47 32.98
TAX 12.53 41.28 -69.65 103.80 100.85 2.93 112.60 -161.24 -169.83
Deferred Tax 7.13 14.49 -50.79 48.67 7.10 585.49 0.03 -194.89 -100.02
PAT 18.16 110.50 -83.57 211.68 423.01 -49.96 519.70 636.71 -18.38
Equity 144.24 144.24 0.00 144.24 144.24 0.00 144.24 144.24 0.00
PBIDTM(%) 15.69 27.16 -42.22 21.12 27.86 -24.18 26.91 27.22 -1.14

Fermenta Biotech Share Price

312.55 -9.30 (-2.89%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×